Introduction: This study investigates the prevalence of dementia in patients with and without schizophrenia, with a particular focus on age-specific and sex-specific differences.
Methods: We conducted a population-based study using the National Health Insurance claims database from 2010 to 2013. Using a 10:1 matching ratio, 248,919 patients without schizophrenia and 26,591 patients with schizophrenia were identified based on the ICD-10 code. Patients with dementia were extracted by diagnosis or use of anti-dementia drugs. Conditional logistic regression analyses were performed to evaluate the association between schizophrenia and dementia.
Results: The prevalence of dementia was significantly higher in schizophrenia patients compared with that in matched non-schizophrenia patients (9.9% versus 2.2%, P < 0.0001). After adjusting for Charlson comorbidity index and underlying comorbidities, conditional logistic regression showed that schizophrenia was associated with dementia (adjusted odds ratio [AOR], 4.7; 95% confidence interval [CI], 4.4-5.1). When stratified by sex, the AOR was 5.6 (95% CI, 5.0-6.2) among women and 4.0 (95% CI, 3.6-4.5) among men. Moreover, the association between dementia and schizophrenia was strong in elderly patients. The AOR of dementia prevalence was 6.6 (95% CI, 6.1-7.2) in patients aged ≥65 years and 3.4 (95% CI, 3.0-3.8) in patients aged <65 years.
Discussion: Schizophrenia patients were more likely to have dementia compared with non-schizophrenia patients. This association seems greater in higher prevalence groups such as women and patients aged ≥65 years. Further investigation on the mechanism is required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/appy.12239 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SchizoLMNet: a modified lightweight MobileNetV2- architecture for automated schizophrenia detection using EEG-derived spectrograms.
Phys Eng Sci Med
January 2025
Department of Electronics and Communication Engineering, Vishnu Institute of Technology, Bhimavaram, Andhra Pradesh, 534202, India.
Schizophrenia (SZ) is a chronic neuropsychiatric disorder characterized by disturbances in cognitive, perceptual, social, emotional, and behavioral functions. The conventional SZ diagnosis relies on subjective assessments of individuals by psychiatrists, which can result in bias, prolonged procedures, and potentially false diagnoses. This emphasizes the crucial need for early detection and treatment of SZ to provide timely support and minimize long-term impacts.
View Article and Find Full Text PDFEfficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.
Neurol Ther
January 2025
Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.
Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).
View Article and Find Full Text PDFTransdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance.
Neuropsychopharmacol Hung
December 2024
Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.
Aims: Autism spectrum disorder and schizophrenia are traditionally viewed as distinct diagnostic categories. However, evidence increasingly suggests overlapping pathological functioning at various levels, starting from brain circuitry to behaviour. Notably, both disorders are characterized by anomalous minimal self-experience (altered body ownership and agency), which is a trait-like, phenomenological distortion.
View Article and Find Full Text PDFEfficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia.
Schizophr Res Cogn
June 2025
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Unlabelled: Despite significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). This double-blind, placebo-controlled, parallel-group Phase II trial assessed the efficacy and safety of pharmacological augmentation of at-home computerized cognitive training (CCT) with iclepertin (BI 425809, a glycine transporter-1 inhibitor). Participants with schizophrenia (aged 18-50 years) on stable antipsychotic therapy, who were compliant with CCT during the run-in period, were enrolled.
View Article and Find Full Text PDFAdvances in transcranial focused ultrasound neuromodulation for mental disorders.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
Department of Rehabilitation, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. Electronic address:
Mental disorders are a major public health concern, affecting millions worldwide. Current treatments have limitations, highlighting the need for novel, effective, and safe interventions. Transcranial focused ultrasound (tFUS), a non-invasive neuromodulation technology, has emerged as a promising tool for treating mental disorders due to its high controllability, precision, and safety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!